Amsterdam UMC continues to advance the practice of high-dose ablative radiation therapy with MRIdian through research and publication of the center's findings.Īmsterdam UMC began treating patients with MRIdian in 2016 and has been a leader in the treatment of prostate, pancreatic, lung, liver, and kidney cancers. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand patients using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy). Cash burn in the fourth quarter ofĪmsterdam University Medical Centers Treats 1,000th Patient with MRIdian SMART MRI-Guided Radiation TherapyĬLEVELAND - ViewRay, Inc. Cash and cash equivalents were approximately $157 million as of December 31, 2020.Total backlog was approximately $241 million as of December 31, 2020.
Vray stock forecast full#
Full year 2020 revenue of approximately $57 million, primarily from nine revenue units, including two system upgrades,Ĭompared to 2019 revenue of approximately $88 million, primarily from 15 revenue units, including two system upgrades.Quarter of 2020, compared to four new orders totaling approximately $21 million in the fourth quarter of 2019. Received five new orders, including one upgrade, for MRIdian systems totaling approximately $24 million in the fourth.System upgrade, in the fourth quarter of 2019. System upgrade, compared to total revenue of approximately $17 million, primarily from three revenue units including one Total revenue of approximately $18 million in the fourth quarter of 2020, primarily from three revenue units including one.Selected Fourth Quarter and Full Year 2020 Preliminary Results and Other Data (Unaudited): The preliminary results have not been audited and are subject to change. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and fullįiscal year ended December 31, 2020. ViewRay Announces Preliminary Fourth Quarter and Full Year 2020 ResultsĬLEVELAND, OH /PRNewswire/ - ViewRay, Inc.
0 kommentar(er)
